Hurdles and delays in access to anti-cancer drugs in Europe.

导出 LinkOut

翻译打印收藏纠错

第一作者： F,Ades

第一单位： Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels 1000, Belgium.

作者： F,Ades ^[1] ; D,Zardavas ^[1] ; C,Senterre ^[2] ; E,de Azambuja ^[1] ; A,Eniu ^[3] ; R,Popescu ^[4] ; M,Piccart ^[1] ; F,Parent ^[5]

作者单位： Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels 1000, Belgium. ^[1] Research Centre of Epidemiology, Biostatistics and Clinical Research, School of Public Health, Université Libre de Bruxelles, Brussels 1050, Belgium. ^[2] Department of Breast Tumours, Cancer institute Ion Chiricuta, Cluj-Napoca RO-400015, Romania. ^[3] Department of Medical Oncology, Hirslanden Clinic Aarau, Aarau 5001, Switzerland. ^[4] Research Centre of Social Approaches of Health, School of Public Health, Université Libre de Bruxelles, Brussels 1050, Belgium. ^[5]

关键词 European Medicines Agency (EMA)European Union drug uptake marketing authorization prescription and compliance pricing and reimbursement

DOI 10.3332/ecancer.2014.482

PMID 25525460

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览81

Ecancermedicalscience

2014年8卷

482页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Hurdles and delays in access to anti-cancer drugs in Europe.

Ecancermedicalscience

相似文献

Ecancermedicalscience

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Hurdles and delays in access to anti-cancer drugs in Europe.

Ecancermedicalscience

相似文献

Ecancermedicalscience

相关期刊

检索历史清除